Compare SBFG & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBFG | PMN |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.8M | 136.2M |
| IPO Year | 2014 | 2022 |
| Metric | SBFG | PMN |
|---|---|---|
| Price | $26.88 | $15.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | ★ 62.8K | 55.9K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 27.33 | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.16 | $0.29 |
| 52 Week High | $27.69 | $27.40 |
| Indicator | SBFG | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 67.71 | 66.97 |
| Support Level | $20.94 | $9.87 |
| Resistance Level | N/A | $19.85 |
| Average True Range (ATR) | 0.99 | 1.40 |
| MACD | 0.09 | 0.16 |
| Stochastic Oscillator | 85.11 | 73.88 |
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.